GlaxoSmithKline Earlier Reported Q4 EPS $0.31 Misses $0.64 Estimate, Sales $11.62B Beat $11.60B Estimate
Portfolio Pulse from Benzinga Newsdesk
GlaxoSmithKline reported a Q4 EPS of $0.31, missing the $0.64 estimate, but sales of $11.62 billion slightly beat the $11.60 billion estimate.
February 03, 2021 | 3:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GlaxoSmithKline's Q4 earnings per share (EPS) of $0.31 fell short of the expected $0.64, indicating potential concerns over profitability. However, sales slightly exceeded expectations at $11.62 billion, which may provide some support to the stock.
The significant miss on EPS suggests potential issues with profitability, which is a critical metric for investors. Although sales were slightly above expectations, the EPS miss is likely to weigh more heavily on investor sentiment, potentially leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100